+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Soft Tissue Sarcoma (STS) - Epidemiology Forecast - 2030

  • ID: 4871929
  • Report
  • February 2020
  • Region: Global
  • 122 pages
  • DelveInsight
1 of 2
‘Soft Tissue Sarcoma (STS) - Epidemiology Forecast-2030' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology trends of STS in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

According to the World Health Organization (WHO), there are more than 50 histologic subtypes of STSs. The signs and symptoms of STSs vary greatly from patients to patients based on the type of STS. However, it is not associated with any noticeable symptoms early in the course of the disease but the affected individuals may notice slow-growing, painless mass in the affected area.

According to the publisher's, STS has various subtypes. It was observed that in the United States and European countries, liposarcoma and leiomyosarcoma were the most incident subtypes of STS, which contributed to the majority of the cases. Whereas in Japan, subtypes, fibroblastic sarcomas and liposarcoma were more common.

Geography Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Soft Tissue Sarcoma (STS) - Disease Understanding

Soft-tissue sarcoma (STS) are rare neoplasms that can develop in supporting or connective tissue, such as the muscle, nerves, tendons, blood vessels and fatty and fibrous tissues. They commonly affect the arms, legs, and trunk. They also appear in the stomach and intestines (GIST) as well as behind the abdomen (retroperitoneal sarcomas) and the female reproductive system (gynecological sarcomas). STSs may be classified according to the involved cell-type, the specific nature of the malignancy, and the disease's clinical course.

Soft Tissue Sarcoma (STS) Epidemiology

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incident Cases of Soft Tissue Sarcoma (STS) in the 7MM, Type-specific Incidence Cases of Soft Tissue Sarcoma in the 7MM, Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States, Total Incident Cases of STS including GIST in the United States and Incidence of STS by Extremities (%) in the 7MM scenario of STS in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2017-2030.

According to the publisher's, the total incident population of Soft Tissue Sarcoma (STS) in seven major markets was 40,155 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).

Among all the seven major markets, the United States accounts for the highest number of cases of STS. In 2017, there were 12,390 incident cases of STS - which did not include GIST cases - in the United States. The total incident cases of GIST which were observed in the United States in 2017 accounted for 5,090. This lead to the total incident population of STS to 17,480 in 2017.

In European countries, GIST cases are not included in the STS population. Germany had the highest incident population of STS with 4,781 cases, followed by Italy which had an incident population of 4,082 in 2017. On the other hand, Spain had the lowest incident population of 2,445 in 2017.

Soft Tissue Sarcoma (STS) Report Insights
  • The report covers a descriptive overview of the Soft Tissue Sarcoma (STS), explaining its causes, risk factors, pathophysiology, and diagnosis.
  • Comprehensive insight has been provided into the epidemiology of Soft Tissue Sarcoma (STS) in the 7MM countries covering the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • Assesses growth opportunities in 7MM countries with respect to the patient population.
Soft Tissue Sarcoma (STS): Report Key Strengths
  • 11 Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation by Total incident cases of STS
  • Total Incident Cases of GIST in the US
  • Stage-specific Incident cases of STS
  • Incidence of STS by Extremities (%)
Key Benefits
  • Key assessments
  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by Severity
Note: Product cover images may vary from those shown
2 of 2
1. Key Insights

2. Executive Summary of Soft-Tissue Sarcoma (STS)

3. Soft-Tissue Sarcomas (STS) Epidemiology Overview at a Glance
3.1. Total Incident Cases of Soft-Tissue Sarcomas (STS) in 2017
3.2. Total Incident Cases of Soft-Tissue Sarcomas (STS) in 2030

4. Soft-Tissue Sarcomas (STS): Disease Background and Overview
4.1. Introduction
4.2. Types of Soft-Tissue Sarcomas (STS)
4.3. The Molecular Biology of Soft-Tissue Sarcomas (STS)
4.4. Stages of Soft-Tissue Sarcomas (STS)
4.5. Diagnosis of Soft-Tissue Sarcomas (STS)
4.5.1. Medical History and Physical Exam
4.5.2. Imaging Tests
4.5.3. Biopsy
4.5.4. Pathological diagnosis of soft tissue sarcomas
4.5.5. Proposed Diagnostic Guidelines

5. Epidemiology and Patient Population
5.1. Key Findings
5.2. Epidem Methodology
5.3. 7MM Incident Patient Population of Soft Tissue Sarcoma (STS)

6. Case Reports
6.1. Neoadjuvant chemotherapy for radiation-associated soft-tissue sarcoma (RAS): A case report
6.2. Soft-Tissue Sarcoma Masquerading as a Hematoma
6.3. Neoadjuvant chemotherapy for primary sarcoma of the breast: a case report

7. Country Wise-Epidemiology of Soft Tissue Sarcoma (STS)
7.1. United States Epidemiology
7.1.1. Assumptions and Rationale
7.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United States
7.1.3. Type-Specific Incidence of STS in the United States
7.1.4. Total Incident Cases of Gastrointestinal Stromal Tumor (GIST) in the United States
7.1.5. Total Incident Cases of STS including GIST in the United States
7.1.6. Incidence of STS by Extremities (%) in the United States
7.2. EU5 Epidemiology
7.2.1. Germany
7.2.1.1. Assumptions and Rationale
7.2.1.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Germany
7.2.1.3. Gender-Specific Incidence of STS in Germany
7.2.1.4. Type-Specific Incidence of STS in Germany
7.2.1.5. Age-Specific Incidence of STS in Germany
7.2.1.6. Stage-Specific Incidence of STS in Germany
7.2.1.7. Incidence of STS by Extremities (%) in Germany
7.2.2. France
7.2.2.1. Assumptions and Rationale
7.2.2.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in France
7.2.2.3. Gender-Specific Incidence of STS in France
7.2.2.4. Type-Specific Incidence of STS in France
7.2.2.5. Age-Specific Incidence of STS in France
7.2.2.6. Stage-Specific Diagnosed Incidence of STS in France
7.2.2.7. Incidence of STS by Extremities (%) in France
7.2.3. Italy
7.2.3.1. Assumptions and Rationale
7.2.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Italy
7.2.3.3. Gender-Specific Incidence of STS in Italy
7.2.3.4. Type-Specific Incidence of STS in Italy
7.2.3.5. Age-Specific Incidence of STS in Italy
7.2.3.6. Stage-Specific Diagnosed Incidence of STS in Italy
7.2.3.7. Incident of STS by Extremities (%) in Italy
7.2.4. Spain
7.2.4.1. Assumptions and Rationale
7.2.4.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Spain
7.2.4.3. Gender-Specific Incidence of STS in Spain
7.2.4.4. Type-Specific Incidence of STS in Spain
7.2.4.5. Age-Specific Incidence of STS in Spain
7.2.4.6. Stage-Specific Incidence of STS in Spain
7.2.4.7. Incident of STS by Extremities (%) in Spain
7.2.5. United Kingdom
7.2.5.1. Assumptions and Rationale
7.2.5.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in the United Kingdom
7.2.5.3. Gender-Specific Incidence of STS in the United Kingdom
7.2.5.4. Type-Specific Incidence of STS in the United Kingdom
7.2.5.5. Age-Specific Incidence of STS in the United Kingdom
7.2.5.6. Stage-Specific Diagnosed Incidence of STS in the United Kingdom
7.2.5.7. Incident of STS by Extremities (%) in the United Kingdom
7.3. Japan Epidemiology
7.3.1. Assumptions and Rationale
7.3.2. Total Incident Cases of Soft Tissue Sarcoma (STS) in Japan
7.3.3. Gender-Specific Incidence of STS in Japan
7.3.4. Type-Specific Incidence of STS in Japan
7.3.5. Age-Specific Incidence of STS in Japan
7.3.6. Stage-Specific Incidence of STS in Japan
7.3.7. Incident of STS by Extremities (%) in Japan

8. Appendix
8.1. Report Methodology

9. Publisher Capabilities

10. Disclaimer

11. About the Publisher
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll